1X. Du,D. Edelstein,M. Brownlee.Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes[J].Diabetologia.2008(10)
2Kumar V,,Ghosh B,Raina UK,et al.Comparative therapy evalu.ation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema[].American Journal of Ophthalmology.2008
3Du X,Edelstein D,Brownlee M.Oral benfotiamine plus alpha.lipoic acid normalises complication.causing pathways in type1diabetes[].Diabetologia.2008
4Hoffmann J,Alt A,Lin J,et al.Tenilsetamprevents early diabet.ic retinopathy without correcting pericyte loss[].Thrombosis and Haemostasis.2006
5.
6PKC-DMES Study Group.Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial[].Archives of Ophthalmology.2007
7Cameron NE,Gibson TM,Nangle MR,et al.Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes[].Annals of the New York Academy of Sciences.2005
8Knopp RH,Emden MD,Smilde JG,et al.Efficacy and safety of atorvas-tatin in the prevention of cardiovascular end points in subjects with type2diabetes.The atorvastatin study for prevention of cardiovascular end points in Non-insulin Dependent Diabetes Mellitus(ASPEN)[].Diabetes Care.2006
同被引文献10
1Scanlon PH,Aldington SJ,Stratton IM.Epidemiological issues in diabetic retinopathy[J].Middle East Afr J Ophthalmol,2013,20(4):293.
2Shah SP,Chen C.Review of therapeutic advances in diabetic retinopathy[J].Ther Adv Endocrinom Metab,2011,2(1):39.
3Karami M,Janghorbani M,Dehghani A,et al.Orbital Doppler evaluation of blood flow velocities in patients with diabetic retinopathy[J].Rev Diabet Stud,2012,9(3):104.
4Qian H,Ripps H.Neurovascular interaction and the pathophysiology of diabetic retinopathy[J].Exp Diabetes Res,2011:69 326.
5Curtis TM,Gardiner TA,Stitt AW.Microvascular lesions of diabetic retinopathy:clues towards understanding pathogenesis?[J].Eye:Lond,2009,23(7):1 496.
